A Combination Chemotherapy Protocol (VELCAP-L) for Dogs with Lymphoma |
| |
| Authors: | Barbara I Zemann Antony S Moore William M Rand Gail Mason David M Ruslander Angela E Frimberger Carrie A Wood Deborah A L'Heureux John Gliatto Susan M Cotter |
| |
| Institution: | School of Veterinary Medicine, Vienna, Austria;Tufts University School of Veterinary Medicine, North Grafton, MA;Tufts Community Health, Boston, MA;Bath-Brunswick Veterinary Associates, Brunswick, ME |
| |
| Abstract: | Ninety-eight dogs with lymphoma treated with a 5-drug combination chemotherapy regimen (vincristine, L-asparaginase. cyclophosphamide, doxorubicin, prednisone VELCAP-L]) were evaluated for pretreatment characteristics predictive for response and remission duration. The complete remission rate was 69%, with a median remission duration of 55 weeks. Dogs with advanced stage of disease, constitutional signs, dogs that were older, and dogs that were dyspneic were less likely to achieve remission. Once in remission, small dogs and dogs without pretreatment thrombocytopenia were likely to have longer remission duration. Toxicoses were frequent, but rarely fatal, and no predictitive factors were found for a dog developing toxicoses. VELCAP-L is an effective treatment for dogs in stage I-III lymphoma, particularly in young, small animals. |
| |
| Keywords: | Cancer Remission Treatment |
|
|
